Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Relapsed/Refractory B-cell NHL With EZH2 Mutation
NCT03456726Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Eisai Co., Ltd.. Started Apr 2018; status: completed.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03456726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456726.